Findlay, David M.

The global threat of antimicrobial resistance: science for intervention.

Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., Cohen, J., Findlay, D., Gyssens, I., Heure, O. E., et al. (2015) · New Microbes and New Infections

Antibiotic Use and ResistanceAntibiotic Resistance in Bacteria

Cited by 1,106

Donepezil and memantine for moderate-to-severe Alzheimer's disease

Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 782

Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway

Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 503

Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain

Zhu, S., Zhu, J., Zhen, G., Hu, Y., An, S., Li, Y., Zheng, Q., Chen, Z., Yang, Y., Wan, M., et al. (2019) · Journal of Clinical Investigation

Osteoarthritis Treatment and MechanismsPain Mechanisms and Treatments

Cited by 456

RANKL Expression Is Related to the Differentiation State of Human Osteoblasts

Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 245

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint

Haynes, D. R., Crotti, T. N., Loric, M., Bain, G. I., Atkins, G. J., & Findlay, D. M. (2001) · Rheumatology

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 216

Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases

Rheumatoid Arthritis Research and TherapiesNatural Compounds in Disease Treatment

Cited by 186

Determining the minimum clinically important differences for outcomes in the DOMINO trial

Howard, R., Phillips, P., Johnson, T., O'Brien, J., Sheehan, B., Lindesay, J., Bentham, P., Burns, A., Ballard, C., Holmes, C., et al. (2011) · International Journal of Geriatric Psychiatry

Dementia and Cognitive Impairment ResearchStatistical Methods in Clinical Trials

Cited by 185

Identification of brain isoforms of the rat calcitonin receptor.

Sexton, P. M., Houssami, S., Hilton, J. M., O'Keeffe, L. M., Center, R. J., Gillespie, M. T., Darcy, P., & Findlay, D. M. (1993) · Molecular Endocrinology

Neuropeptides and Animal PhysiologyReceptor Mechanisms and Signaling

Cited by 134

The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis

Fazzalari, N. L., Kuliwaba, J. S., Atkins, G. J., Forwood, M. R., & Findlay, D. M. (2001) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 129

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2l/trail‐induced apoptosis

Evdokiou, A., Bouralexis, S., Atkins, G. J., Chai, F., Hay, S., Clayer, M., & Findlay, D. M. (2002) · International Journal of Cancer

Cell death mechanisms and regulationSarcoma Diagnosis and Treatment

Cited by 129

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone

Bone Metabolism and DiseasesBone Tumor Diagnosis and Treatments

Cited by 105

Calcitonin: Physiology or fantasy?

Davey, R. A., & Findlay, D. M. (2013) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesParathyroid Disorders and Treatments

Cited by 101

Calcitonin Receptor Plays a Physiological Role to Protect Against Hypercalcemia in Mice

Davey, R. A., Turner, A. G., McManus, J. F., Chiu, W. M., Tjahyono, F., Moore, A. J., Atkins, G. J., Anderson, P. H., Ma, C., Glatt, V., et al. (2008) · Journal of Bone and Mineral Research

Parathyroid Disorders and TreatmentsBone Metabolism and Diseases

Cited by 87

Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.

Tsangari, H., Findlay, D. M., Kuliwaba, J. S., Atkins, G. J., & Fazzalari, N. L. (2004) · Bone

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 69

A Role for the Calcitonin Receptor to Limit Bone Loss During Lactation in Female Mice by Inhibiting Osteocytic Osteolysis

Clarke, M. V., Russell, P. K., Findlay, D. M., Sastra, S., Anderson, P. H., Skinner, J. P., Atkins, G. J., Zajac, J. D., & Davey, R. A. (2015) · Endocrinology

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 54

Mini ReviewCalcitonin

Findlay, D. M., & Sexton, P. M. (2004) · Growth Factors

Parathyroid Disorders and TreatmentsNeuropeptides and Animal Physiology

Cited by 54

Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01)

Michelangeli, V. P., Findlay, D. M., Fletcher, A., & Martin, T. J. (1986) · Calcified Tissue International

Neuropeptides and Animal PhysiologyBone Metabolism and Diseases

Cited by 49

Calcitonin receptor down-regulation relates to calcitonin resistance in mature mouse osteoclasts.

Wada, S., Udagawa, N., Nagata, N., Martin, T. J., & Findlay, D. M. (1996) · Endocrinology

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 47

The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption

Turner, A. G., Tjahyono, F., Chiu, W. S. M., Skinner, J., Sawyer, R., Moore, A. J., Morris, H. A., Findlay, D. M., Zajac, J. D., & Davey, R. A. (2011) · Bone

Bone Metabolism and DiseasesParathyroid Disorders and Treatments

Cited by 39

Peroxidase enzymes inhibit osteoclast differentiation and bone resorption

Panagopoulos, V., Liapis, V., Zinonos, I., Hay, S., Leach, D. A., Ingman, W., DeNichilo, M. O., Atkins, G. J., Findlay, D. M., Zannettino, A. C. W., et al. (2017) · Molecular and Cellular Endocrinology

Bone Metabolism and DiseasesNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 18

Calcitonin

Findlay, D. M., Sexton, P. M., & Martin, T. J. (2016) · Endocrinology: Adult and Pediatric

Parathyroid Disorders and TreatmentsBone health and osteoporosis research

Cited by 2